-
Financial Report -Pfizer
contractpharma
April 30, 2020
Biopharma revenues up 11% in the quarter to $10.0 billion; generic competition impacts Upjohn revenues.
-
Cambrex Completes Biopharma Expansion
contractpharma
April 08, 2020
The Durham, NC site now features a range of new instruments, including particle analysis and imaging.
-
Biopharma industry leaders collaborate to combat COVID-19
europeanpharmaceuticalreview
March 30, 2020
The International Federation of Pharmaceutical Manufacturers and Associations has announced that the biopharma industry has responding swiftly to the COVID-19 pandemic and will further increase its efforts.
-
Thermo Fisher Scientific Continues Biopharma Investments
contractpharma
March 24, 2020
Further invests $475 million in biopharma capabilities to help accelerate commercialization.
-
The top 10 largest biopharma M&A deals in 2019
fiercepharma
January 07, 2020
Biopharma M&A got a big boost moneywise in 2019. The three largest—Bristol-Myers Squibb for Celgene, AbbVie for Allergan, and Amgen for Celgene’s psoriasis drug Otezla—together delivered more than $150 billion. Valued at $74 billion ...
-
Evolving World of Pharma: Demand for biologics is predicted to grow at 10% per year over the next 4-5 years
Sarah Harding
November 24, 2019
As biopharmaceuticals continue to grow at a rapid place, a number of trends are impacting industry.
-
U.S. biopharma CEOs look outside for growth, poll finds
fiercepharma
September 26, 2019
Eli Lilly went after Loxo Oncology to beef up its presence in cancer treatment, just as Amgen is paying $13.4 billion for Celgene’s Otezla to secure a larger share of the psoriasis market alongside old TNF drug Enbrel.
-
WCG KMR group invites Biopharma companies to enroll in Clinical Trial Cost Study
biospectrumasia
September 20, 2019
All of WCG KMR Group's studies are built upon a comprehensive yet granular framework that allows for the maximum level of detail in performance reporting.
-
Rentschler Biopharma Takes on New Projects at Milford, MA Facility
contractpharma
September 05, 2019
The site will support both clinical and commercial manufacturing programs .
-
Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab
b3cnewswire
July 09, 2019
Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab.